Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, the Centers for ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

He also articulated a very specific doctrine about the role of an FDA commissioner, one that is limited in its power and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

Lilly is making Mounjaro available to the NHS at a confidential discount to the drug's list price of between £92 and £122 – depending on dose – for a four-week supply of the drug.

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first ... was the first drug to be approved for alopecia ...

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...